

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

John S. Millar, ... , Henry N. Ginsberg, Daniel J. Rader

J Clin Invest. 2016;**126**(4):1603-1604. <https://doi.org/10.1172/JCI87364>.

Corrigendum

Original citation: *J Clin Invest.* 2015;**125**(6):2510–2522. doi:10.1172/JCI80025. Citation for this corrigendum: *J Clin Invest.* 2016;**126**(4):1603–1604. doi:10.1172/JCI87364. In Table 4, the units for ApoC-III conc. were incorrect. The correct table is below. The authors regret the error.

Find the latest version:

<https://jci.me/87364/pdf>



Retraction

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

Rosa Marina Melillo, Maria Domenica Castellone, Valentina Guarino, Valentina De Falco, Anna Maria Cirafici, Giuliana Salvatore, Fiorina Caiazzo, Fulvio Basolo, Riccardo Giannini, Mogens Kruhoffer, Torben Orntoft, Alfredo Fusco, and Massimo Santoro

Original citation: *J Clin Invest.* 2005;115(4):1068-1081. doi:10.1172/JCI22758.

Citation for this retraction: *J Clin Invest.* 2016;126(4):1603. doi:10.1172/JCI87345.

At the request of the corresponding author, the *JCI* is retracting this manuscript. The corresponding author recently notified the *JCI* that multiple microscopy images in Figure 2B were previously published and were used to represent different samples in another publication by the corresponding author's group (1). The authors have stated that experimental data produced ad hoc are consistent with those in the original publication; however, the paper is being retracted due to data duplication and misrepresentation in the original publication.

1. Melillo RM, et al. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. *Am J Pathol.* 2004;165(2):511-521.

Erratum

A role for genetic susceptibility in sporadic focal segmental glomerulosclerosis

Haiyang Yu, Mykyta Artomov, Sebastian Brähler, M. Christine Stander, Ghaidan Shamsan, Matthew G. Sampson, J. Michael White, Matthias Kretzler, Jeffrey H. Miner, Sanjay Jain, Cheryl A. Winkler, Robi D. Mitra, Jeffrey B. Kopp, Mark J. Daly, and Andrey S. Shaw

Original citation: *J Clin Invest.* 2016;126(3):1067-1078. doi:10.1172/JCI82592.

Citation for this erratum: *J Clin Invest.* 2016;126(4):1603. doi:10.1172/JCI87342.

The scatter graph in Figure 4G was incorrect in the print version and the original online version of this article; a correct version of the latter has since been published. The correct figure panel is at right.

The *JCI* regrets the error.

Corrigendum

Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects

John S. Millar, Gisette Reyes-Soffer, Patricia Jumes, Richard L. Dunbar, Emil M. deGoma, Amanda L. Baer, Wahida Karmally, Daniel S. Donovan, Hashmi Rafeek, Laura Pollan, Junichiro Tohyama, Amy O. Johnson-Levonas, John A. Wagner, Stephen Holleran, Joseph Obunike, Yang Liu, Rajasekhar Ramakrishnan, Michael E. Lassman, David E. Gutstein, Henry N. Ginsberg, and Daniel J. Rader

Original citation: *J Clin Invest.* 2015;125(6):2510-2522. doi:10.1172/JCI80025.

Citation for this corrigendum: *J Clin Invest.* 2016;126(4):1603-1604. doi:10.1172/JCI87364.

In Table 4, the units for ApoC-III conc. were incorrect. The correct table is below.

The authors regret the error.




Table 4. Factors known to be associated with ApoB clearance: mean baseline values, percentage change from baseline, and between-period differences for subjects in the total population and by panel

	Panel A (n = 29)			Panel B (n = 10)			All subjects (n = 39)				
	Period 1 (ATV)	Period 2 (ANA + ATV)	% Change from period 1 (95% CI)	Period 1 (PBO)	Period 2 (ANA)	% Change from period 1 (95% CI)	P value	Period 1	Period 2	% Change from period 1 (95% CI)	P value
HL conc. (ng/ml)	0.25 ^b (41.26)	0.23 (31.04)	-8.6 (-20.6, 5.3)	0.22 ^b (29.52)	0.25 ^b (57.86)	17.4 (-8.5, 50.8)	0.200	0.23 ^b (39.04)	0.24 ^b (37.79)	3.6 (-10.2, 19.6)	0.620
HL activity ^a (μmol FA liberated/ml plasma/h)	1.77 ^b (2.51)	1.25 ^b (3.04)	-12.5 (-29.41, 9.27)	1.58 (1.60)	2.27 (1.71)	7.3 (-52.32, 83.42)	0.255	1.75 ^b (2.33)	1.46 ^b (2.68)	-3.5 (-22.20, 15.49)	0.606
LPL conc. ^a (mg/ml)	253.5 ^b (115.5)	297.0 (112.0)	6.2 (-4.92, 20.40)	261.0 ^b (48.0)	277.0 ^b (59.0)	3.06 (-12.65, 20.71)	0.264	257.0 ^b (98.0)	287.0 ^b (101.0)	4.9 (-3.69, 15.60)	0.255
LPL activity ^a (μmol FA liberated/ml plasma/h)	2.59 ^b (2.70)	2.17 ^b (2.13)	-16.8 (-49.92, 19.79)	3.84 (2.08)	2.53 (2.82)	-35.3 (-72.71, 31.78)	0.339	2.62 ^b (2.66)	2.24 ^b (2.47)	-22.1 (-47.05, 8.25)	0.161
Lathosterol ^a (mg/dl)	0.03 (0.03)	0.03 (0.03)	0.0 (-8.71, 46.25)	0.13 (0.08)	0.10 (0.04)	-11.5 (-30.99, 21.75)	0.106	0.04 (0.05)	0.04 (0.08)	0.0 (-11.53, 23.53)	0.383
ApoC-II conc. ^a (mg/dl)	4.4 (1.3)	5.2 (1.5)	16.1 (7.67, 25.77)	5.2 (3.1)	6.4 (2.1)	11.3 (-2.78, 27.45)	<0.001 ^c	4.4 (1.5)	5.6 (2.1)	15.2 (7.69, 22.90)	0.001
ApoC-III conc. (mg/dl)	7.4 (40.8)	11.1 (44.4)	49.6 (28.89, 73.71)	8.37 (35.2)	10.5 (64.6)	24.9 (-31.6, 60.98)	<0.001	7.9 (39.4)	10.7 (49.1)	36.7 (17.96, 58.39)	0.001
ApoE conc. ^a (mg/dl)	3.3 (0.8)	4.3 (2.1)	25.4 (12.39, 42.75)	4.4 (0.8)	5.1 (3.9)	19.8 (-7.89, 52.18)	<0.001 ^c	3.7 (0.8)	4.3 (2.2)	23.7 (12.19, 38.08)	<0.001
LDL size ^a (nM)	49.80 (9.30)	48.90 (9.30)	0.4 (-4.22, 6.25)	53.25 (5.30)	47.95 (7.90)	-10.3 (-19.48, -0.19)	0.848	51.00 (10.60)	48.90 (8.40)	-2.8 (-6.26, 2.77)	0.380
LDL size ^a (nM)	21.00 (1.00)	22.10 (1.20)	4.2 (2.30, 5.98)	20.60 (0.80)	21.80 (1.80)	4.3 (0.72, 8.11)	<0.001	20.90 (1.00)	22.10 (1.30)	4.3 (2.69, 5.82)	<0.001

Mixed-model analysis was performed on a log scale for the endpoints that satisfied normality. Geometric mean (% CV) is displayed under "Period 1" and "Period 2." Geometric mean ratio (95% CI) is displayed under "% Change from period 1." Nonparametric method was used. Median (IQR) on a raw scale is displayed under "Period 1" and "Period 2." Hodges-Lehmann estimate (95% CI) back-transformed from a log scale is displayed under "% Change from period 1." P value by Wilcoxon signed-rank test. ^aData for 1 subject is missing in each of the following: Panel A, period 1 and panel B, periods 1 and 2 for HL concentration; panel A, period 1 and panel B, periods 1 and 2 for LPL concentration; and panel A, periods 1 and 2 for HL activity and LPL activity. Panel A, period 1: 20 mg ATV + PBO. Panel A, period 2: 20 mg ATV + 100 mg anacetrapib. Panel B, period 1: PBO to ATV + PBO. Panel B, period 2: PBO to ATV + 100 mg anacetrapib. ^cSignificant between-groups difference with an FDR of less than 5% after multiplicity adjustment. FA, fatty acid; conc., concentration.